iBio shares soar another 174% on hopes for China vaccine partnership - (MarketWatch via NewsPoints Desk)

  • Shares of iBio surged another 174% on Friday, bringing the company's weekly gain to 689%, on hopes for its partnership with Beijing CC-Pharming on a plant-based vaccine for COVID-19, reported MarketWatch.

  • The partnership aims to leverage CC-Pharming's work on MERS, another coronavirus, and iBio's manufacturing processes in plant-based expression systems.

  • The news was first announced in early February with iBio aiming to use its FastPharming facility, which was set up to create rapid delivery of medical countermeasures to treat a pandemic.

To read more NewsPoints articles, click here.